FHI Clinical Inc. Providing Services for ACTT-1 Trial of Remdesivir for COVID-19 Treatment
FHI Clinical Inc. has announced that it has a subcontract with the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide clinical operations services for the Adaptive COVID-19 Treatment Trial (ACTT). ACTT is an adaptive study to allow investigation of putative therapeutics, for the treatment of COVID-19 in hospitalized adults.
Supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the ongoing ACTT study is a randomized, double-blinded, placebo-controlled trial. Preliminary results of the first iteration from ACTT-1 were published in the New England Journal of Medicine (NEJM) for 1,063 participants recruited within an eight-week period at 60 study sites and 13 subsites in Denmark, Germany, Greece, Japan, Korea, Mexico, Singapore, Spain, the United Kingdom and the United States.
The FHI Clinical team provides a variety of clinical operations services and expertise for this study, including trial master file (TMF) management, site management tasks such as regulatory document collection, operational communications and responses, study team meeting coordination, and 24/7 call center oversight and staffing.
In this first iteration of the trial, in addition to standard care, intravenous remdesivir or placebo was administered for up to 10 days to determine the effect on recovery time. Due to the rapid enrollment pace, an interim review by the Data and Safety Monitoring Board (DSMB) occurred after enrollment was completed but while follow-up was ongoing.
The preliminary analysis demonstrated that adults hospitalized with COVID-19 receiving remdesivir showed shorter time to recovery, 11 days compared with 15 days for the placebo group, as well as lower mortality rates. The rates of adverse events were similar between the groups.
The next iteration of the study, known as ACTT-2, is now open, and new participants are receiving remdesivir plus an anti-inflammatory drug (baricitinib) or remdesivir alone.
“The FHI Clinical team is excited to be part of this important work to find efficacious and safe treatments for COVID-19,” said Ted FitzGerald, FHI Clinical president and CEO. “Our team was able to jump in and make an immediate impact given our extensive experience managing studies around the globe.”
Of the FHI Clinical study team members, Danielle Fisher, Associate Director of Clinical Operations, and Wendi McDonald, Clinical Research Associate, are listed in the NEJM paper for their contributions to the study. A new paper will be published in the NEJM once follow-up is complete and results from the full analyses are available.
To learn more:
- Review the National Institutes of Health’s summary of study
- Visit clinicaltrials.gov for additional information about the study
This project was funded, in whole with federal funds from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), under 75N91019D00024.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
